SU-11739

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[(4-methylpiperazin-1-yl)methyl]phenyl]amino]-N-(pyridin-3-ylmethyl)pyrimidine-5-carboxamide | image = SU-11739.svg | image2 = | width = | alt = | caption = Chemical structure of SU-11739 | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 123456 | DrugBank = | ChemSpiderID = 123456 | UNII = | KEGG = | ChEBI = | ChEMBL = | C=22 | H=26 | N=6 | O=1 | smiles = | InChI = | InChIKey = }}

SU-11739 is an experimental pharmaceutical drug that has been investigated for its potential use in treating various cancers. It is a small molecule inhibitor that targets specific tyrosine kinases involved in the signaling pathways that regulate cell growth and survival.

Mechanism of Action

SU-11739 functions primarily as a tyrosine kinase inhibitor. Tyrosine kinases are enzymes that play a crucial role in the signaling pathways of cells, particularly in the regulation of cell division and survival. By inhibiting these enzymes, SU-11739 can potentially disrupt the growth and proliferation of cancer cells.

Development and Research

Research on SU-11739 has focused on its efficacy in inhibiting the growth of various cancer cell lines. Preclinical studies have shown that SU-11739 can effectively inhibit the activity of certain tyrosine kinases, leading to reduced tumor growth in animal models. However, as of the latest updates, SU-11739 remains in the experimental stage and has not yet been approved for clinical use.

Potential Applications

The primary application of SU-11739 is in the treatment of oncological conditions. Its ability to target specific signaling pathways makes it a promising candidate for the treatment of cancers that are driven by aberrant tyrosine kinase activity. Researchers are particularly interested in its application for solid tumors and hematological malignancies.

Challenges and Considerations

While SU-11739 shows promise, there are several challenges that need to be addressed before it can be considered for clinical use. These include determining the optimal dosing regimen, understanding potential side effects, and evaluating its efficacy in combination with other cancer therapies. Additionally, the development of resistance to tyrosine kinase inhibitors is a known issue, and strategies to overcome or prevent resistance are an important area of ongoing research.

Related Pages

• Tyrosine kinase inhibitor
• Cancer treatment
• Signal transduction